Get the Stockscreener App
25.87
4.44%
1.10
Zymeworks Bc Inc stock is traded at $25.87, with a volume of 277.90K.
It is up +4.44% in the last 24 hours and down -0.69% over the past month.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
See More
Previous Close:
$24.77
Open:
$25.19
24h Volume:
277.90K
Relative Volume:
0.21
Market Cap:
$1.86B
Revenue:
$81.26M
Net Income/Loss:
$-102.66M
P/E Ratio:
-18.91
EPS:
-1.3678
Net Cash Flow:
$-77.62M
1W Performance:
+2.41%
1M Performance:
-0.69%
6M Performance:
-6.71%
1Y Performance:
+38.94%
1-Day Range:
$25.18
$26.21
1-Week Range:
$24.60
$26.34
52-Week Range:
$16.00
$31.34
Zymeworks Bc Inc Stock (ZYME) Company Profile
Name
Zymeworks Bc Inc
Sector
Industry
Phone
302-274-8744
Address
108 PATRIOT DRIVE, SUITE A, MIDDLETOWN
Compare ZYME vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Bc Inc
|
25.87 | 1.86B | 81.26M | -102.66M | -77.62M | -1.3678 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zymeworks Bc Inc Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-29-26 | Initiated | TD Cowen | Buy |
| Sep-17-26 | Initiated | Wolfe Research | Outperform |
| Aug-26-26 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-26 | Resumed | Truist | Buy |
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-24-25 | Resumed | Wells Fargo | Equal Weight |
| Oct-14-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Bc Inc Stock (ZYME) Latest News
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results - GlobeNewswire Inc.
Zymeworks EVP Schayowitz sells $357,557 in shares By Investing.com - Investing.com Nigeria
Diluted shares outstanding of Zymeworks Inc. – HAN:ZA8 - TradingView
Form 4 Zymeworks Inc For: 12 October By Investing.com - Investing.com Nigeria
Zymeworks EVP Adam Schayowitz sells $357,557 in shares - Investing.com
Zymeworks EVP Adam Schayowitz sells $357,557 in ZYME stock for taxes - Investing.com
Zymeworks EVP, head of R&D Adam Schayowitz sells $357,557 in stock. - Investing.com
Form 4 Zymeworks Inc For: 9 October By Investing.com - Investing.com South Africa
Zymeworks (NASDAQ:ZYME) Stock: Insider Adam Schayowitz Sells 13,832 Shares - MarketBeat
A mandatory sale covers taxes: Zymeworks (ZYME) R&D head sells 13,832 shares at $25.85. - Stock Titan
Form 144 Zymeworks Inc. For: 9 October By Investing.com - Investing.com Nigeria
Officer Adam Schayowitz proposes selling 13,832 shares of Zymeworks (Nasdaq: ZYME). - Stock Titan
Jefferies keeps Buy on Zymeworks stock at USD 50 target - AD HOC NEWS
Zymeworks stock fell 2.14 percent as 2026 guidance reset - AD HOC NEWS
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook - TradingView
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook - Yahoo Finance
EBIT per share of Zymeworks Inc. – HAN:ZA8 - TradingView
CapEx per share of Zymeworks Inc. – HAN:ZA8 - TradingView
Taxes of Zymeworks Inc. – HAN:ZA8 - TradingView
Zymeworks stock coverage reinstated at Buy by TD Cowen on acquisition - Investing.com Nigeria
Citigroup keeps 'Buy' on Zymeworks after acquis... - Pluang
Zymeworks stock coverage reinstated at Buy by TD Cowen on acquisition - Investing.com Canada
Dilution adjustment of Zymeworks Inc. – HAN:ZA8 - TradingView
Zymeworks Inc. (ZYME) stock price, news, quote and history - Yahoo Finance UK
Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Eyes Growth in COPD Market - GuruFocus
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal - TradingView
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal - Benzinga
Zymeworks Completes Theravance Acquisition Deal - grafa.com
Zymeworks Inc. Updates Earnings Guidance for the Year 2026 - marketscreener.com
Zymeworks Inc. Updates Earnings Guidance for the Year 2026 - marketscreener.com
Zymeworks Inc. (ZYME) Theravance Biopharma, Inc.M&A CallSlideshow (NASDAQ:ZYME) 2026-09-28 - Seeking Alpha
Zymeworks Inc. and Theravance Biopharma, Inc. Acquisition Call Transcript - GuruFocus
Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Int - GuruFocus
Zymeworks Inc Expects Total Revenue, Including Collaboration Revenue From Yupelri, For 2026 To Be Between $278 Million And $292 Million - TradingView
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition - GlobeNewswire Inc.
Zymeworks Announces Updated 2026 Financial Guidance and - GlobeNewswire
Bank of America Corp DE Buys 219,071 Shares of Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition - Yahoo Finance
Vancouver biotech Zymeworks closes US$929M Theravance deal - Business in Vancouver
A $350 million debt issue helped fund Zymeworks (ZYME)'s Theravance acquisition, with cash due per eligible share. - Stock Titan
Zymeworks Completes Acquisition of Theravance Biopharma - GlobeNewswire
Zymeworks Completes Acquisition of Theravance Biopharma - Yahoo Finance
Squarepoint Ops LLC Reduces Holdings in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow (NASDAQ:ZYME) - Seeking Alpha
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 238,026 Shares of Zymeworks Inc. $ZYME - MarketBeat
Wellington Management Group LLP Takes $2.88 Million Position in Zymeworks Inc. $ZYME - MarketBeat
Legal & General Group Plc Makes New $1.13 Million Investment in Zymeworks Inc. $ZYME - MarketBeat
Bank of New York Mellon Corp Acquires New Holdings in Zymeworks Inc. $ZYME - MarketBeat
JPMorgan Chase & Co. Boosts Zymeworks (NASDAQ:ZYME) Price Target to $33.00 - MarketBeat
Zymeworks (NASDAQ:ZYME) Hits New 1-Year HighTime to Buy? - MarketBeat
Zymeworks Bc Inc Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zymeworks Bc Inc Stock (ZYME) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Adam Schayowitz | officer |
Oct 09 '26 |
Proposed Sale |
25.26 |
13,832 |
349,396 |
0 |
| Schayowitz Adam | EVP, Head of R&D |
Oct 09 '26 |
Sale |
25.85 |
13,832 |
357,557 |
23,205 |
| Jeffrey T L Smith | Former Officer |
Mar 06 '26 |
Proposed Sale |
24.80 |
247,333 |
6,133,858 |
0 |
| Leone D Patterson | Former officer |
Feb 17 '26 |
Proposed Sale |
22.60 |
31,641 |
715,087 |
0 |
| Leone D Patterson | Former officer |
Feb 13 '26 |
Proposed Sale |
23.17 |
128,548 |
2,978,457 |
0 |
| Kenneth Galbraith | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
30,424 |
704,924 |
0 |
| Paul Andrew Moore | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
9,560 |
221,505 |
0 |
| Jeffrey T L Smith | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
9,310 |
215,713 |
0 |
| Mark Hollywood | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
6,120 |
141,800 |
0 |
| Hollywood Mark | EVP & Chief Operating Officer |
Jan 12 '26 |
Option Exercise |
0.00 |
17,666 |
0 |
139,033 |
5.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):